Emergent BioSolutions Inc. · NYSE:EBS
Emergent BioSolutions — J.P. Morgan Healthcare Conference 2017
18 slides from Emergent BioSolutions's conference presentation, Jan 9, 2017
Slide 1: Corporate Update
Corporate Update Daniel J. Abdun-NabiPresident and CEO J.P. Morgan Healthcare ConferenceJanuary 10, 2017
Slide 2: Forward-Looking Statements
Forward-Looking StatementsThis presentation includes forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Any statements, other than statements of historical fact, including, without limitation, our financial guidance, and any other statements contai
Slide 3: Emergent BioSolutions: Who we are
Emergent BioSolutions: Who we are OVER1200EMPLOYEES 10GLOBAL LOCATIONS 6MARKETEDPRODUCTS EXPERTISE AT5MANUFACTURINGLOCATIONS SERVICESCMO, BULK,FILL / FINISH As a global specialty life sciences company, Emergent is focused on providing specialty products for civilian and military populations that add
Slide 4: Rising Global Threat Matrix
Rising Global Threat Matrix Public Health Threats: “Time bomb: ISIS has recruited an army of scientists and already smuggled chemical and biological weapons into Europe.” European Parliament Report “Antibiotic resistance is rising to dangerously high levels in all parts of the world. New resistance
Slide 5: Growth Drivers
Growth Drivers Total Annual US Funding for Health Security: ~$13 Billion Per Year Since 2010Source: Health Security. 2016 Sep-Oct; 14(5): 284-304 US Government ResponseContinued focus on preparednessCreating a sustainable enterprise to foster innovation, e.g., Priority Review Vouchers International
Slide 6: What We Do: Products, Pipeline, Platforms & Services
What We Do Products, Pipeline, Platforms & Services
Slide 7: Portfolio of Medical Countermeasures
Portfolio of Medical Countermeasures BioThrax® Anthrax Vaccine Anthrasil™ Anthrax Therapeutic (Hyperimmune) BAT® Botulism Therapeutic (Hyperimmune) VIGIV Vaccinia Therapeuticfor Smallpox Vaccine(Hyperimmune) Marketed products PRODUCTS TARGETINGCHEMICAL THREATS PRODUCTS TARGETINGBIOLOGICAL THREATS Re
Slide 8: Pipeline: Creating Future Growth
Product Government Partner Platform PRV Potential Threat Type Pre Clinical CLINICAL PHASE I II III NuThrax™Next generation anthrax vaccine BARDA $1.5B Development & Procurement Contract - - Biological 2018* FLU-IGSeasonal Influenza therapeutic - Hyperimmune - EID 2017* UV-4BDengue therapeutic NIH -
Slide 9: Manufacturing Expertise
Manufacturing Expertise Center for Innovation in Advanced Development and Manufacturing (CIADM)One of three in the United StatesPublic private partnership with BARDASurge capacity readiness and infrastructure for biologics-based MCMsFlexible manufacturing to address biological threats and EIDs3 Task
Slide 10: Financial & Operational Performance
Financial & Operational Performance
Slide 11: 2016 Year in Review
2016 Year in Review Aptevo TherapeuticsSPIN-OFF Building 55FDA APPROVAL BioThrax ProcurementNEW CDC Contract PRELIMINARY UNAUDITED FINANCIAL RESULTS OPERATIONAL GOALS ADDITIONAL ACCOMPLISHMENTS Combined Basis Continuing Operations Total revenue $500M - $505M $480M - $485M Net income $44M - $48M (GAA
Slide 12: Financial Performance 2012-2016
Financial Performance 2012-2016 revenue Net income CASH EBITDA Notes: - All values shown in $ millions - 2016E values assume mid-point of range of estimated CY2016 financial results. - All data are shown on a combined basis, which includes operations associated with the Company’s former biosciences
Slide 13: Roadmap: Business Foundation & Goals
Roadmap: Business Foundation & Goals STRATEGY COMPETENCIES ExpandPHT MarketLeadershipPosition Partner toDevelopInnovativeProducts GrowThroughAcquisitions Expand Portfolio ofMCMs & Services GovernmentRelations &Contracting MCM Development &Commercialization QualityManufacturing Business &ProductAcqui
Slide 14: 2017 Goals
Initiate two human factor formative studies for nerve agent antidote auto-injector Advance NuThrax development to enable theinitiation of a Phase III study in 2018 2017 Goals FINANCIAL OPERATIONAL Total revenue $500M - $530M Net income $60M - $70M (GAAP) $70M - $80M (Adjusted) EBITDA $135M - $145M D
Slide 15: Long Term Vision
Long Term Vision The public health threat market is growing Our portfolio is unique and well positioned Our strategy is aligned to address a broad rangeof threats and dual market opportunities
Slide 16: Appendix: Reconciliation Tables
Appendix Reconciliation Tables
Slide 17: Reconciliation of Net Income to Adjusted Net Income
Reconciliation of Net Income to Adjusted Net Income Reconciliation Tables COMBINED BASIS CONTINUING OPERATIONS BASIS The combined basis reflects the company’s operations including the operations of the former biosciences business that was spun-off as Aptevo Therapeutics in August 2016. The continuin
Slide 18: Reconciliation of Net Income to EBITDA
Reconciliation of Net Income to EBITDA Reconciliation Tables COMBINED BASIS CONTINUING OPERATIONS BASIS The combined basis reflects the company’s operations including the operations of the former biosciences business that was spun-off as Aptevo Therapeutics in August 2016. The continuing operations
Emergent BioSolutions — J.P. Morgan Healthcare Conference 2017 on 6ix